Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Nature medicine, 2018•nature.com
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion
with CD19–leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was
unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its
product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from
recognition by and conferring resistance to CTL019.
with CD19–leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was
unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its
product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from
recognition by and conferring resistance to CTL019.
Abstract
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19– leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.
nature.com